Roche country medical director Richard Woodfield said the registration of TECENTRIQ SC is “a critical step in making this first-in-class anti-PD-L1 formulation available for eligible patients." …
Roche welcomes registration of the first subcutaneous PD-L1 cancer immunotherapy
March 4, 2024 Latest NewsBioPharma
Latest Video
New Stories
-
Stakeholder backing for another PBS co-pay reduction
March 20, 2025 - - Latest News -
If our own government isn't going to do anything, then we can only hope for intervention
March 20, 2025 - - Latest News -
US price negotiation power reveals a very different approach to patient input
March 20, 2025 - - Latest News -
Brisbane-based drugmaker QBiotics celebrates 25 years since its creation
March 19, 2025 - - Australian Biotech -
Imugene's azer-cel granted FDA Fast Track Designation in blood cancer
March 19, 2025 - - Australian Biotech -
Island raises $2.72 million through exercise of listed options
March 19, 2025 - - Australian Biotech -
All manufacturers decide to participate in the second cycle of US price negotiation
March 19, 2025 - - Latest News